Copyright Reports & Markets. All rights reserved.

Global Benign Prostate Hyperplasia Drugs Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Alpha Blocker
      • 1.4.3 5-Alpha Reductase Inhibitor
      • 1.4.4 Phosphodiesterase-5 Inhibitor
      • 1.4.5 Others
    • 1.5 Market by Application
      • 1.5.1 Global Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2025)
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Benign Prostate Hyperplasia Drugs Market Size
    • 2.2 Benign Prostate Hyperplasia Drugs Growth Trends by Regions
      • 2.2.1 Benign Prostate Hyperplasia Drugs Market Size by Regions (2019-2025)
      • 2.2.2 Benign Prostate Hyperplasia Drugs Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Benign Prostate Hyperplasia Drugs Market Size by by Players
      • 3.1.1 Global Benign Prostate Hyperplasia Drugs Revenue by by Players (2014-2019)
      • 3.1.2 Global Benign Prostate Hyperplasia Drugs Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Benign Prostate Hyperplasia Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Benign Prostate Hyperplasia Drugs Key Players Head office and Area Served
    • 3.3 Key Players Benign Prostate Hyperplasia Drugs Product/Solution/Service
    • 3.4 Date of Enter into Benign Prostate Hyperplasia Drugs Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Benign Prostate Hyperplasia Drugs Market Size by Type (2014-2019)
    • 4.2 Global Benign Prostate Hyperplasia Drugs Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
    • 5.2 Benign Prostate Hyperplasia Drugs Key Players in North America
    • 5.3 North America Benign Prostate Hyperplasia Drugs Market Size by Type
    • 5.4 North America Benign Prostate Hyperplasia Drugs Market Size by Application

    6 Europe

    • 6.1 Europe Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
    • 6.2 Benign Prostate Hyperplasia Drugs Key Players in Europe
    • 6.3 Europe Benign Prostate Hyperplasia Drugs Market Size by Type
    • 6.4 Europe Benign Prostate Hyperplasia Drugs Market Size by Application

    7 China

    • 7.1 China Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
    • 7.2 Benign Prostate Hyperplasia Drugs Key Players in China
    • 7.3 China Benign Prostate Hyperplasia Drugs Market Size by Type
    • 7.4 China Benign Prostate Hyperplasia Drugs Market Size by Application

    8 Japan

    • 8.1 Japan Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
    • 8.2 Benign Prostate Hyperplasia Drugs Key Players in Japan
    • 8.3 Japan Benign Prostate Hyperplasia Drugs Market Size by Type
    • 8.4 Japan Benign Prostate Hyperplasia Drugs Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
    • 9.2 Benign Prostate Hyperplasia Drugs Key Players in Southeast Asia
    • 9.3 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size by Type
    • 9.4 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size by Application

    10 India

    • 10.1 India Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
    • 10.2 Benign Prostate Hyperplasia Drugs Key Players in India
    • 10.3 India Benign Prostate Hyperplasia Drugs Market Size by Type
    • 10.4 India Benign Prostate Hyperplasia Drugs Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
    • 11.2 Benign Prostate Hyperplasia Drugs Key Players in Central & South America
    • 11.3 Central & South America Benign Prostate Hyperplasia Drugs Market Size by Type
    • 11.4 Central & South America Benign Prostate Hyperplasia Drugs Market Size by Application

    12 International Players Profiles

    • 12.1 Sanofi
      • 12.1.1 Sanofi Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Benign Prostate Hyperplasia Drugs Introduction
      • 12.1.4 Sanofi Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019))
      • 12.1.5 Sanofi Recent Development
    • 12.2 Coloplast
      • 12.2.1 Coloplast Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Benign Prostate Hyperplasia Drugs Introduction
      • 12.2.4 Coloplast Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
      • 12.2.5 Coloplast Recent Development
    • 12.3 Pfizer
      • 12.3.1 Pfizer Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Benign Prostate Hyperplasia Drugs Introduction
      • 12.3.4 Pfizer Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
      • 12.3.5 Pfizer Recent Development
    • 12.4 Merck
      • 12.4.1 Merck Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Benign Prostate Hyperplasia Drugs Introduction
      • 12.4.4 Merck Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
      • 12.4.5 Merck Recent Development
    • 12.5 GlaxoSmithKline
      • 12.5.1 GlaxoSmithKline Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Benign Prostate Hyperplasia Drugs Introduction
      • 12.5.4 GlaxoSmithKline Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
      • 12.5.5 GlaxoSmithKline Recent Development
    • 12.6 Eli Lilly and Company
      • 12.6.1 Eli Lilly and Company Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Benign Prostate Hyperplasia Drugs Introduction
      • 12.6.4 Eli Lilly and Company Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
      • 12.6.5 Eli Lilly and Company Recent Development
    • 12.7 Abbott Laboratories
      • 12.7.1 Abbott Laboratories Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Benign Prostate Hyperplasia Drugs Introduction
      • 12.7.4 Abbott Laboratories Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
      • 12.7.5 Abbott Laboratories Recent Development
    • 12.8 Teva Pharmaceuticals
      • 12.8.1 Teva Pharmaceuticals Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Benign Prostate Hyperplasia Drugs Introduction
      • 12.8.4 Teva Pharmaceuticals Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
      • 12.8.5 Teva Pharmaceuticals Recent Development
    • 12.9 Allergan
      • 12.9.1 Allergan Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Benign Prostate Hyperplasia Drugs Introduction
      • 12.9.4 Allergan Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
      • 12.9.5 Allergan Recent Development
    • 12.10 Boehringer Ingelheim
      • 12.10.1 Boehringer Ingelheim Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Benign Prostate Hyperplasia Drugs Introduction
      • 12.10.4 Boehringer Ingelheim Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
      • 12.10.5 Boehringer Ingelheim Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      This report focuses on the global Benign Prostate Hyperplasia Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Benign Prostate Hyperplasia Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Sanofi
      Coloplast
      Pfizer
      Merck
      GlaxoSmithKline
      Eli Lilly and Company
      Abbott Laboratories
      Teva Pharmaceuticals
      Allergan
      Boehringer Ingelheim

      Market segment by Type, the product can be split into
      Alpha Blocker
      5-Alpha Reductase Inhibitor
      Phosphodiesterase-5 Inhibitor
      Others

      Market segment by Application, split into
      Hospital
      Clinic
      Other

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Benign Prostate Hyperplasia Drugs status, future forecast, growth opportunity, key market and key players.
      To present the Benign Prostate Hyperplasia Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Benign Prostate Hyperplasia Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now